Connect with us

Business

Telix (ASX:TLX) share price on watch amid clinical trial news

Published

on

ADVERTISEMENT

The Telix Pharmaceuticals Ltd (ASX: TLX) share price will be in focus today after the company announced its prostate cancer therapy has been approved for stage III clinical trials.

Shares in the company closed last session trading at $3.94.

The biopharmaceutical company’s prostate cancer…



Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

These buy-rated ASX shares are growing rapidly
Is the Fortescue (ASX:FMG) share price a buy with a potential 21% yield?